Moderna, Inc. $MRNA Shares Newly Bought by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,725 shares of the company’s stock, valued at approximately $525,000.

Other hedge funds also recently bought and sold shares of the company. Ethic Inc. boosted its stake in Moderna by 23.6% in the 3rd quarter. Ethic Inc. now owns 19,394 shares of the company’s stock worth $3,735,000 after purchasing an additional 3,700 shares during the period. Merck & Co. Inc. acquired a new stake in Moderna during the 2nd quarter valued at $161,642,545. Bank of New York Mellon Corp acquired a new stake in Moderna during the 2nd quarter valued at $119,168,000. Contravisory Investment Management Inc. raised its stake in Moderna by 1,387.6% during the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after purchasing an additional 22,590 shares during the period. Finally, TD Waterhouse Canada Inc. lifted its holdings in shares of Moderna by 2,042.6% in the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after purchasing an additional 69,203 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent analyst reports. Morgan Stanley raised their target price on Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Loop Capital set a $135.00 price target on Moderna in a research report on Wednesday, August 19th. Rothschild & Co Redburn downgraded Moderna from a “neutral” rating to a “sell” rating and increased their price objective for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Jefferies Financial Group reissued a “hold” rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Finally, The Goldman Sachs Group raised their price objective on Moderna from $137.00 to $195.00 and gave the stock a “neutral” rating in a research report on Monday, November 9th. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $113.75.

View Our Latest Research Report on Moderna

Key Stories Impacting Moderna

Investors following MRNA have been watching these stories:

  • Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
  • Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
  • Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Insider Activity at Moderna

In related news, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the sale, the president owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $223.37 on Monday. The company has a 50 day moving average of $201.67 and a two-hundred day moving average of $96.41. The company has a market cap of $90.38 billion, a price-to-earnings ratio of -31.46 and a beta of 1.16. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same period in the previous year, the company posted ($0.51) EPS. Moderna’s revenue was up 29.2% on a year-over-year basis. On average, equities analysts anticipate that Moderna, Inc. will post -5.14 earnings per share for the current fiscal year.

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.